Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer

被引:14
作者
Planas, Jacques [1 ]
Celma, Ana [1 ]
Placer, Jose [1 ]
Cuadras, Merce [1 ]
Regis, Lucas [1 ]
Gasanz, Carlos [1 ]
Trilla, Enrique [1 ]
Salvador, Carlos [1 ]
Lorente, David [1 ]
Morote, Juan [1 ]
机构
[1] Univ Autonoma Barcelona, Hosp Vall dHebron, Dept Urol, Barcelona, Spain
关键词
Androgen deprivation therapy; castration level; luteinizing hormone; prostate cancer; testosterone; SERUM TESTOSTERONE; CESSATION; AGONIST; TIME; MEN; NORMALIZATION; SUPPRESSION; WITHDRAWAL; CARCINOMA; TRENDS;
D O I
10.1080/21681805.2016.1227876
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: The aim of this study was to evaluate hormonal recovery after cessation of androgen deprivation therapy (ADT) in a group of elderly prostate cancer patients. Materials and methods: Forty patients with locally advanced or metastatic prostate cancer, with a mean age of 71.5 years [95% confidence interval (CI) 69.1-73.9], were treated with ADT for a mean duration of 74.6 months (95% CI 59.7-89.5 months). Mean follow-up time after ADT cessation was 36.5 months (95% CI 30.6-42.3 months). Serum testosterone and luteinizing hormone (LH) were determined at 6 month intervals after ADT cessation. Results: After 18 months of follow-up, all patients had recovered normal LH levels, while 38% of patients still presented castration levels of testosterone (< 50 ng/dl). A multivariate analysis was performed to find factors related to testosterone recovery (testosterone >50 ng/dl). Neither age at start of ADT nor clinical stage reached statistical significance. Only time under ADT was correlated with testosterone recovery (p = .031). Kaplan-Meier curves were obtained. Mean time for testosterone recovery was 14.5 months (95% CI 6.5-22.6 months) in patients treated with ADT for less than 60 months compared to 29.3 months (95% CI 19.6-39.1 months) in patients treated with ADT for more than 60 months (log-rank p = .029). Conclusions: Age did not correlate with testosterone recovery in a group of elderly prostate cancer patients in whom ADT was stopped. Testosterone recovery after ADT cessation was significantly correlated with time under ADT treatment. Significant implications related to economic aspects of the dosage schedule may be considered.
引用
收藏
页码:425 / 428
页数:4
相关论文
共 16 条
  • [1] Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective
    Akaza, H
    [J]. CANCER SCIENCE, 2006, 97 (04) : 243 - 247
  • [2] Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer
    Bong, Gary W.
    Clarke, Harry S., Jr.
    Hancock, Wanda C.
    Keane, Thomas E.
    [J]. UROLOGY, 2008, 71 (06) : 1177 - 1180
  • [3] National practice patterns and time trends in androgen ablation for localized prostate cancer
    Cooperberg, MR
    Grossfeld, GD
    Lubeck, DP
    Carroll, PR
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (13) : 981 - 989
  • [4] Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy
    Crook, Juanita M.
    O'Callaghan, Christopher J.
    Duncan, Graeme
    Dearnaley, David P.
    Higano, Celestia S.
    Horwitz, Eric M.
    Frymire, Eliot
    Malone, Shawn
    Chin, Joseph
    Nabid, Abdenour
    Warde, Padraig
    Corbett, Thomas
    Angyalfi, Steve
    Goldenberg, S. Larry
    Gospodarowicz, Mary K.
    Saad, Fred
    Logue, John P.
    Hall, Emma
    Schellhammer, Paul F.
    Ding, Keyue
    Klotz, Laurence
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (10) : 895 - 903
  • [5] DAEHLIN L, 1988, SCAND J UROL NEPHROL, V22, P11
  • [6] Cessation of Primary Androgen Deprivation Therapy for Men With Localized Prostate Cancer
    Fujimoto, Naohiro
    Kubo, Tatsuhiko
    Tomisaki, Ikko
    [J]. CLINICAL GENITOURINARY CANCER, 2015, 13 (04) : 359 - 363
  • [7] Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer
    Hall, MC
    Fritzsch, RJ
    Sagalowsky, AI
    Ahrens, A
    Petty, B
    Roehrborn, CG
    [J]. UROLOGY, 1999, 53 (05) : 898 - 902
  • [8] Longitudinal effects of aging on serum total and free testosterone levels in healthy men
    Harman, SM
    Metter, EJ
    Tobin, JD
    Pearson, J
    Blackman, MR
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (02) : 724 - 731
  • [9] TESTICULAR HISTOLOGY AFTER TREATMENT WITH LH-RH ANALOG FOR CARCINOMA OF THE PROSTATE
    JOHANSEN, TEB
    OGREID, P
    KJELLEVOLD, KK
    BLOM, P
    [J]. BRITISH JOURNAL OF UROLOGY, 1990, 65 (04): : 376 - 378
  • [10] Kaku H, 2002, NIPPON RINSHO, V11, P182